Kazuki Sato
Has grant
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Mechanism of T cell receptor signaling by phase separation and its application to artificially control regulatory T cells in the tumor environment.
Open Date: 2022-04-01
Close Date: 2024-03-01
Grant: Close
Elucidation of DNAM-1 mediated activation mechanism of type 3 innate lymphoid cells in inflammatory bowel disease
Open Date: 2021-04-01
Close Date: 2023-03-01
Grant: Close
Elucidation of the regulatory mechanism of regulatory T cell activation via DNAM-1 in graft versus host disease
Open Date: 2019-04-01
Close Date: 2021-03-01
Grant: Close
Elucidation of apoptosis B cell elimination by follicular dendritic cells and their physiological significance
Open Date: 2014-04-01
Close Date: 2017-03-01
Articles (2)
Phospholipase C gamma 1 ( PLCG1 ) has been identified as the most frequently mutated gene in adult T-cell leukemia/lymphoma, suggesting a critical function of PLCG1 in driving T cell activation. However, it remains unclear how these mutations regulate T cell physiology and pathology. Here, we investigate three common leukemia/lymphoma-associated mutations (R48W, S345F, and D1165H). We discover that these mutations induce hyperactive T cell signaling and cause pro-survival phenotypes. PLCG1 mutants enhance LAT condensation, calcium influx, and ERK activation. They also promote T cell proliferation, upregulate cell adhesion molecules, induce cell aggregation, and confer resistance to Vorinostat, an FDA-approved drug for cutaneous T-cell lymphoma. The resistance depends on ERK signaling and can be reversed with an ERK inhibitor. Interestingly, PLCG1 mutants also induce bystander drug resistance in nearby cells expressing wild-type PLCG1. Mechanistically, alpha smooth muscle actin, which is specifically induced by PLCG1 mutants, directly binds PLCG1 to promote its activation. These results demonstrate that hyperactive PLCG1 promotes T cell survival and drug resistance by inducing non-canonical signaling.
Year:
2025
Chimeric antigen receptor (CAR)-T cell therapies have shown remarkable efficacies for treating otherwise intractable cancers. However, current clinically approved CAR-T therapies are limited by low antigen sensitivity, impeding their efficacy against cancers with low antigen expression. Here, to address this issue, we engineered CARs targeting CD19, CD22 and HER2 by including intrinsically disordered regions (IDRs) that promote signaling condensation. We discovered that the CAR fused with an IDR from FUS, EWS or TAF15 promoted the formation of CAR-T conjugation with cancer targets, the mechanical strength of CAR-T synapses and membrane-proximal signaling, which led to an increased release of cytotoxic factors and a higher killing activity toward low-antigen-expressing cancer cells in vitro. Moreover, the FUS IDR CAR-T induced improved antitumor effects in both blood cancer and solid tumor models. No spontaneous activation in the absence of antigen was observed. Together, our work demonstrates IDRs as a new toolset for improving CAR-T function through inducing biomolecular condensation.
Year:
2025
Collaborators (2)
Qian Xiao
Principal Investigator
Rutgers Cancer Institute of New Jersey
Yasunori Kogure
Senior Researcher
National Cancer Center Research Institute
Make your next move.
Prepare your application
Review drafts before you send them.